Foundational Pharmacy Strategies’ Christine Johnston on how rebate structures, pending legislation, and a stalled pipeline are reshaping — and threatening — the biosimilar market heading into 2027.
News|Articles|April 6, 2007
Disclosure Form (PDF)
All authors contributing manuscripts for consideration for publication in Formulary must disclose any real or apparent conflicts of interest due to affiliation with any company or manufacturer whose products are mentioned in the article they author.
Advertisement
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Why biosimilars keep losing ground to brand-name rivals: A Q&A with Christine Johnston, MBA
2
Pope Leo XIV's lung cancer diagnosis puts a spotlight on low U.S. screening rates
3
Chronic hand eczema needs more than topical steroids | Fall Clinical Derm 2026
4
Choosing a first biologic for HS, as recommended by Jennifer Hsiao, M.D. | Fall Clinical Derm 2026
5